dosReis Susan, Espinal Pena Dafne, Fincannon Alexandra, Gorman Emily F, Amill-Rosario Alejandro
Department of Practice, Science, and Health Outcomes Research, School of Pharmacy, University of Maryland Baltimore, Baltimore, MD, 21201, USA.
Department of Practice, Science, and Health Outcomes Research, School of Pharmacy, PAVE Center, Baltimore, MD, USA.
Patient. 2025 Jan;18(1):19-33. doi: 10.1007/s40271-024-00706-6. Epub 2024 Jul 5.
Individual preferences for treatment options for major depressive disorder can impact therapeutic decision making, adherence, and ultimately outcomes.
This systematic review of discrete choice experiments (DCEs) on patient preferences for major depressive disorder treatment assessed the range of DCE applications in major depressive disorder to document patient stakeholder involvement in DCE development and to identify the relative importance of treatment attributes.
We searched MEDLINE via Ovid (1946-present), EMBASE (Elsevier interface), Cochrane Central Register of Controlled Trials (Wiley interface), and PsycINFO (EBSCO interface) databases on 29 May, 2024. Covidence software facilitated the review, which four members completed independently. The review was conducted in two phases: title and abstract and then a full-text review. We used an established quality reporting tool to evaluate selected articles. The Covidence extraction tool was adapted for this study.
A total of 19 articles were included in this review. Most studies elicited preferences for depression treatment (63.2%) and care delivery (10.5%). Two assessed willingness to pay. Individuals prefer a combination of medicine and counseling over each treatment alone. Treatment efficacy, relapse prevention, and symptom relief were among the most important attributes. Individuals were willing to accept larger risks to achieve symptom improvement. Few studies examined preference heterogeneity with latent subgroups.
Discrete choice experiments for major depressive disorder treatment preferences enable an assessment of trade-offs for first-line therapeutic options. Patient stakeholders are infrequently involved as collaborators in the DCE development. Few examined preference heterogeneity among subgroups.
对于重度抑郁症治疗方案的个人偏好会影响治疗决策、依从性以及最终的治疗结果。
这项关于患者对重度抑郁症治疗偏好的离散选择实验（DCE）的系统评价，评估了DCE在重度抑郁症中的应用范围，以记录患者利益相关者在DCE开发中的参与情况，并确定治疗属性的相对重要性。
我们于2024年5月29日通过Ovid检索了MEDLINE（1946年至今）、EMBASE（爱思唯尔界面）、Cochrane对照试验中心注册库（威利界面）和PsycINFO（EBSCO界面）数据库。Covidence软件辅助了此次评价，由四名成员独立完成。评价分两个阶段进行：标题和摘要筛选，然后是全文筛选。我们使用一种既定的质量报告工具来评估所选文章。Covidence提取工具针对本研究进行了调整。
本评价共纳入19篇文章。大多数研究引出了对抑郁症治疗（63.2%）和护理提供（10.5%）的偏好。两项研究评估了支付意愿。比起单独的每种治疗，个体更喜欢药物和咨询相结合的方式。治疗效果、预防复发和症状缓解是最重要的属性。个体愿意接受更大的风险以实现症状改善。很少有研究用潜在亚组来检验偏好异质性。
针对重度抑郁症治疗偏好的离散选择实验能够评估一线治疗方案的权衡取舍。患者利益相关者很少作为合作者参与DCE的开发。很少有研究检验亚组之间的偏好异质性。
